Literature DB >> 17802919

Antibiotic use: present and future.

Stephen H Zinner1.   

Abstract

Antibiotics were initially viewed as "wonder drugs" primarily because they were introduced at a time when only surgical drainage or spontaneous cures were available to treat serious bacterial infections. During the five or six decades since their introduction, several classes of these drugs became available including sulfonamides and trimethoprim, penicillins, cephalosporins, chloramphenicol, tetracyclines, colimycins, macrolides, lincosamides, streptogramins, rifamycins, glycopeptides, aminoglycosides, fluoroquinolones, oxazolidinones, glycylglycines, lipoglycopeptides, and variations on these themes. Unfortunately, through a variety of mechanisms and perhaps as a result of their profligate use, many bacterial groups are exhibiting resistance to these antibiotics. At present, most bacterial infections can still be treated with available antibiotics used alone or in combination, but increasing numbers of clinical failures with the current armamentarium can be expected. Optimizing drug dosing and duration might help minimize the emergence of resistance in some situations. However, the future could look dim, as there are relatively few new agents on the horizon. A bold new look for antibacterial targets is needed. Surely our scientific abilities are up to this challenge. New approaches to antimicrobial chemotherapy are needed if we are to survive the increasing rates of antibiotic resistance predicted for the future.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17802919

Source DB:  PubMed          Journal:  New Microbiol        ISSN: 1121-7138            Impact factor:   2.479


  10 in total

1.  Rapid universal identification of bacterial pathogens from clinical cultures by using a novel sloppy molecular beacon melting temperature signature technique.

Authors:  Soumitesh Chakravorty; Bola Aladegbami; Michele Burday; Michael Levi; Salvatore A E Marras; Darshini Shah; Hiyam H El-Hajj; Fred Russell Kramer; David Alland
Journal:  J Clin Microbiol       Date:  2009-11-18       Impact factor: 5.948

2.  Impairment of ribosomal subunit synthesis in aminoglycoside-treated ribonuclease mutants of Escherichia coli.

Authors:  Ashley D Frazier; W S Champney
Journal:  Arch Microbiol       Date:  2012-08-29       Impact factor: 2.552

3.  Inhibition of antibiotic-resistant Staphylococcus aureus by the broad-spectrum dihydrofolate reductase inhibitor RAB1.

Authors:  C R Bourne; E W Barrow; R A Bunce; P C Bourne; K D Berlin; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2010-07-06       Impact factor: 5.191

Review 4.  Antibacterial, Antifungal, Antiviral, and Antiparasitic Activities of Peganum harmala and Its Ingredients: A Review.

Authors:  Zihao Zhu; Shujuan Zhao; Changhong Wang
Journal:  Molecules       Date:  2022-06-29       Impact factor: 4.927

5.  Crystal structure of Bacillus anthracis dihydrofolate reductase with the dihydrophthalazine-based trimethoprim derivative RAB1 provides a structural explanation of potency and selectivity.

Authors:  Christina R Bourne; Richard A Bunce; Philip C Bourne; K Darrell Berlin; Esther W Barrow; William W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

Review 6.  The use of platensimycin and platencin to fight antibiotic resistance.

Authors:  Adil M Allahverdiyev; Melahat Bagirova; Emrah Sefik Abamor; Sezen Canim Ates; Rabia Cakir Koc; Meral Miraloglu; Serhat Elcicek; Serkan Yaman; Gokce Unal
Journal:  Infect Drug Resist       Date:  2013-09-18       Impact factor: 4.003

Review 7.  Host Defence Peptides: A Potent Alternative to Combat Antimicrobial Resistance in the Era of the COVID-19 Pandemic.

Authors:  Waqas Ali; Ahmad Elsahn; Darren S J Ting; Harminder S Dua; Imran Mohammed
Journal:  Antibiotics (Basel)       Date:  2022-04-01

8.  A. caviae infection triggers IL-1β secretion through activating NLRP3 inflammasome mediated by NF-κB signaling pathway partly in a TLR2 dependent manner.

Authors:  Qiankun Yang; Jianguo Zhang; Feixue Liu; Huizhen Chen; Wei Zhang; Haitao Yang; Nana He; Jingquan Dong; Panpan Zhao
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

9.  Application of metagenomic next-generation sequencing in cutaneous tuberculosis.

Authors:  Min Kong; Wei Li; Qingsheng Kong; Haixin Dong; Aizhong Han; Liqing Jiang
Journal:  Front Cell Infect Microbiol       Date:  2022-09-23       Impact factor: 6.073

10.  Small molecule modulation of microbiota: a systems pharmacology perspective.

Authors:  Qiao Liu; Bohyun Lee; Lei Xie
Journal:  BMC Bioinformatics       Date:  2022-09-29       Impact factor: 3.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.